Welcome to our dedicated page for AI Financial SEC filings (Ticker: ALTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AI Financial's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AI Financial's regulatory disclosures and financial reporting.
David C. Danziger, a director of ALT5 Sigma Corp (ALTS), filed an Initial Statement of Beneficial Ownership (Form 3) dated 07/02/2025. The filing reports no securities beneficially owned by the reporting person at the time of the statement. The form confirms the reporting relationship as a director and was filed by a single reporting person.
ALT5 Sigma Corporation is updating investors on its previously announced plan to separate into two companies and finance Alyea Therapeutics Corporation independently. A planned spin-off or similar transaction of Alyea will not take place using the earlier disclosed June 2, 2025 record date and may not occur under the previously communicated timeline. The Company states that, if it proceeds with a spin-off or similar transaction, it will later announce details such as a new record date, structure, and timing. ALT5 Sigma highlights its continued confidence in Alyea’s non-addictive pain treatment patents and potential progression to the next stage of clinical trials, and notes that it is continuing to evaluate strategic options to maximize and realize Alyea’s value.
ALT5 Sigma Corporation is soliciting shareholder votes on four proposals tied to a Private Placement that gives the Lead Investor the right to appoint a second director to the board. The board recommends shareholders vote FOR the Issuance, Appointment, Authorized Shares and Adjournment proposals. The filing shows ExodusPoint Capital Management, LP holds 5,856,700 shares, representing 5.34% of voting power. The document includes a proposed certificate amendment and standard proxy background and solicitation details. Several sections of the filing appear partially redacted or truncated, limiting visibility into full Private Placement terms, purchase price, and the exact change to authorized shares.